Angiodynamics reports strong fiscal year 2025 fourth quarter and full year financial results; continued execution driving accelerated, profitable growth

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2025, which ended may 31, 2025. fiscal year 2025 fourth quarter highlights   quarter ended may 31, 2025 pro forma* yoy growth pro forma* net sales $80.2.
ANGO Ratings Summary
ANGO Quant Ranking